Media

In The Media

A next-generation GPCR drug discovery platform based on rational de-novo design & high-throughput optical pooled screening.

The appointments add deep DMPK and data engineering expertise to Skape Bio's platform and pipeline

Jan Voss shares Skape Bio's platform for turning molecular hypotheses into functional GPCR hits through de novo design

Matt Barnes joins Skape Bio to lead translation of AI-designed miniprotein therapeutics into future medicines

CEO Christoffer Norn shares how Skape Bio combines AI design and human-cell screening for GPCR discovery

Emil Hertz presents Skape Bio's high-throughput screening platform for AI-designed GPCR modulators in human cells

CEO Christoffer Norn joins industry leaders to explore AI's role in the future of biotechnology

CEO Christoffer Norn traces Skape Bio's journey from Denmark to the University of Washington

CEO Christoffer Norn and the panel discuss gut health and therapeutic development for consumer health impact

Company enters the Platinum Program, a highly competitive international program in the life sciences

Preprint in bioRxiv details de novo design of miniprotein modulators targeting G protein-coupled receptors

Designed, Not Discovered